The purpose of this guidance is to identify the types of decision support software functionalities that: (1) do not meet the definition of a device as amended by the Cures Act; (2) may meet the definition of a device but for which FDA does not intend to enforce compliance with applicable requirements of the FD&C Act, including, but not limited to, premarket clearance and premarket approval requirements; and (3) FDA intends to focus its regulatory oversight on.
News & Trends
Procurar
Recentes
- Plano de Controlo de Qualidade e Conformidade Legal de SUPLEMENTOS ALIMENTARES: ” Formação muito útil para o desempenho das minhas funções “
- MHRA Registration of medical devices
- The Use of Data in Public Health. Understanding the Potential for Artificial Intelligence in Medicine
- UK Government confirms indefinite recognition of CE marked medical devices
- Methodological Principles for the Assessment of Section 5.1 of the Summary of Product Characteristics
- Good manufacturing practice (GMP) Multistakeholder workshop on expert contributions to artificial intelligence guidance development (Annex 22)
- PIC/S PE 009-18 – Guide to GMP for Medicinal Products | Part I
- EMA Updates Information Page on Bioequivalence Guidelines